Compare CHRW & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHRW | EXAS |
|---|---|---|
| Founded | 1905 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 19.7B |
| IPO Year | 1997 | 2000 |
| Metric | CHRW | EXAS |
|---|---|---|
| Price | $167.79 | $104.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 17 |
| Target Price | ★ $174.53 | $86.62 |
| AVG Volume (30 Days) | 1.5M | ★ 2.4M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | 25.13 | ★ 80.32 |
| EPS | ★ 4.83 | N/A |
| Revenue | ★ $14,869,380,000.00 | $4,144,000.00 |
| Revenue This Year | $4.33 | $15.31 |
| Revenue Next Year | $6.54 | $12.37 |
| P/E Ratio | $35.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $84.68 | $38.88 |
| 52 Week High | $203.34 | $104.98 |
| Indicator | CHRW | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 72.80 |
| Support Level | $148.27 | $103.10 |
| Resistance Level | $167.90 | N/A |
| Average True Range (ATR) | 5.23 | 0.29 |
| MACD | -0.67 | 0.04 |
| Stochastic Oscillator | 11.46 | 97.61 |
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.